SEC Filing Summary: ChromaDex Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on October 29, 2018, reporting events occurring on October 23, 2018. The registrant is incorporated in Delaware and operates from Irvine, California. The filing addresses a change in senior management under Item 5.02.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding personnel changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the voluntary resignation of Troy Rhonemus from his position as Executive Vice President. His resignation is effective as of November 20, 2018.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the executive departure. No unusual items were disclosed.
Key Facts for Investor Verification
- Executive Departure: Troy Rhonemus is resigning as Executive Vice President effective November 20, 2018.
- Reason for Departure: The resignation is voluntary.
- Succession Plan: The filing does not disclose a replacement or interim arrangement for the Executive Vice President role.
- Company Name Discrepancy: The user request referenced "Niagen Bioscience, Inc.," but the filing is for "ChromaDex Corporation." Investors should verify the correct entity.